Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
View Top Employees from Celldex TherapeuticsWebsite | http://www.celldex.com |
Ticker | CLDX |
Revenue | $9 million |
Employees | 195 (166 on RocketReach) |
Founded | 1983 |
Address | 53 Frontage Road Suite 220, Hampton, New Jersey 08827, US |
Phone | (908) 200-7500 |
Fax | (908) 454-1911 |
Technologies |
JavaScript,
HTML,
PHP
+35 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Immuno-oncology, Healthcare, Science and Engineering, Therapeutic antibodies, Health Care, Antibody drug conjugates, Pharmaceutical, Immune system modulators, Immunotherapies, Oncology |
Web Rank | 2 Million |
Keywords | Immunotherapy, Cancer Therapeutics, Targeted Cancer Therapies |
Competitors | Allakos Inc, Dendreon, MIS.CARBONART, MacroGenics, Inc., Sorrento Therapeutics, Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Celldex Therapeutics employee's phone or email?
The Celldex Therapeutics annual revenue was $9 million in 2024.
Freddy Alejandro Jimenez is the Senior Vice-President and General Counsel of Celldex Therapeutics.
166 people are employed at Celldex Therapeutics.
Celldex Therapeutics is based in Hampton, New Jersey.
The NAICS codes for Celldex Therapeutics are [32, 3254, 32541, 325].
The SIC codes for Celldex Therapeutics are [283, 28].